Media

Media contact

Media library

Fast facts

Page last modified 13 March 2019

Compliance Hotline Report Adverse Drug Reaction

You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.

Choose region and then country

Other Lundbeck sites

Global contacts

Media

Welcome to the media section

Latest releases

FDA approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine

Lundbeck increases its share capital by 11,497 shares (0.0058 % of outstanding shares) as a result of exercise of employee warrants

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Annual Report 2019 for H. Lundbeck A/S

Strong momentum with 28% growth across all strategic brands in 2019. For 2020, Lundbeck expects revenue growth of 2-6%

Media contact

General press enquiries, please call +45 3643 4000

Media library

Access visual aids for stories about Lundbeck

Fast facts

Get a quick overview of Lundbeck and our business